For developers of in vivo therapeutics, 2026 marks a shift in where the fastest and most decisive clinical signals are emerging. While the United States and Europe continue to develop regulatory standards, the momentum driving early in vivo human data is increasingly coming from Asia. China, in particular, has become a central player for rapid first-in-human progress through its Investigator Initiated Trial (IIT) ecosystem.
This trend is reshaping how companies across the United States, Europe, and Asia approach clinical strategy, early validation, and manufacturing partnerships. The insights below outline why Asia has become a critical part of global in vivo development and how drug developers can incorporate these learnings into their own pipelines.
Why Asia Has Become the Fastest Route to EarlyIn Vivo Proof of Concept
Asia has quickly become a leading region for generating early feasibility data in in vivo programs. Developers like EsoBiotec have generated early in vivo feasibility data that supported its acquisition by AstraZeneca in a deal valued at up to $1 billion, and Pregene Biopharma, whose emerging in vivo capabilities contributed to a major partnership with Kite Pharma worth up to $1.64 billion. These interactions highlight how early readouts originating from China are increasingly shaping global valuation, partnership decisions, and strategic dealmaking.
Momentum is also building across China’s in vivo CAR-T landscape, where multiple teams are presenting emerging clinical activity and safety insights despite the modality’s early maturity. These developments are contributing to a more competitive, data-rich environment than many Western developers anticipate.
What Makes Asia’s IIT Environment Attractive for In Vivo Developers
Accelerated Timelines
Asia’s regulatory and ethical frameworks for IITs allow qualified investigators to initiate studies more rapidly while maintaining clinical oversight. As a result, sponsors can achieve first-in-human feasibility in months rather than years, which is especially valuable for programs that require rapid iteration or early proof-of-concept readouts.
Cost Efficiency and Early Feasibility
Compared to traditional Western pathways, IITs can reduce early clinical costs. This is particularly advantageous for in vivo modalities where vector development, manufacturing, and delivery optimization often require significant upfront investment.
Expanding Clinical and Manufacturing Capacity
Asia is scaling manufacturing capacity for vectors, LNPs, and gene editing components at a pace that supports accelerated clinical timelines. Many U.S. developers are now turning to Chinese CDMOs to support both IIT execution and broader development needs, including vector supply and formulation work.
The Role of Chinese Biotechs in Shaping the Global Competitive Landscape
China’s in vivo biotech landscape is expanding rapidly, with estimates suggesting that between one hundred and two hundred companies are now active in this space. This growth has produced a continuous stream of early clinical activity, heightened competition and increased investor confidence.
The region’s innovation trajectory has also prompted the introduction of a dedicated “Spotlight on In Vivo Development in Asia” workshop at the summit. This workshop provides scientific, strategic, and operational insights for teams evaluating Asia for early clinical development.
What the “Asia Spotlight” Workshop Will Cover:
The workshop brings together experts from Alaya.bio, Stylus Medicine, and more to address practical questions frequently raised by global developers.
Topics include:
- Study design and clinical planning for IITs, including eligibility criteria, monitoring practices, and the design elements required to ensure data utility across regions
- CMC planning and manufacturing coordination with Asian CDMOs for vector and LNP production
- Regulatory, ethical, and data quality considerations, focusing on how to ensure IIT data aligns with global expectations
- Models for collaboration between Asian and Western developers, including partnerships with biotechs, academic groups and CROs
- Decision criteria for pursuing IITs, including timelines, feasibility, indication suitability, and manufacturing readiness
Why Asia’s Acceleration Matters for Companies With In Vivo Pipelines
For active in vivo developers, incorporating Asia into global planning is becoming a competitive requirement, not a secondary consideration.
Faster Proof of Concept Means Faster Valuation Events
Early signals emerging from Asia have directly contributed to major Western acquisitions and partnerships, showing how accelerated IIT readouts can influence company trajectories.
Asia’s Data Influence Is Growing
Investors and global sponsors view well designed IITs in Asia as meaningful evidence of feasibility when study design and data quality are aligned with international standards.
Manufacturing Partnerships Are Becoming More Important
Asian CDMOs are becoming essential to scaling in vivo manufacturing capacity, supporting both early feasibility studies and broader development pipelines.
Global Strategy Requires Cross Regional Understanding
Developers must understand the scientific, regulatory, and operational differences between running studies in Asia versus the United States or Europe.
How Developers Can Use Asia Insights to Strengthen Their Pipeline Strategy
Whether your company is considering IITs for the first time or are already evaluating Asia for later-stage trials, the summit provides actionable insights to support:
- Planning first-in-human strategies for in vivo programs
- Identifying CRO and CDMO partners with Asia-based expertise
- Navigating data portability between Asia and Western regulatory bodies
- Understanding ethical and quality considerations for IIT design
- Building clinical timelines that reflect Asia’s accelerated environment
- Partnering with Chinese companies that are rapidly innovating in in vivo delivery and editing
Asia is no longer an optional add‑on for in vivo developers. Its combination of rapid early human data, expanding manufacturing networks, and fast‑moving regulatory pathways is reshaping global expectations and investment behavior.
For teams looking to advance or accelerate clinical development in 2026, understanding Asia’s IIT environment is becoming fundamental to competitive positioning.
Explore the Full Program
View the detailed agenda, featured speakers, session highlights, and networking opportunities shaping the fastest‑growing frontier in cell and gene therapy.
Secure Your Place
Join the only meeting dedicated to accelerating in vivo cell engineering and gene editing. Connect with global leaders, access exclusive clinical insights for first-in-human trials, and strengthen your development and delivery strategies.
Showcase Your Capabilities
Position your organization in front of senior R&D and CMC decision-makers at the forefront of this growing field. Attendees are seeking CDMOs, CROs, and vector design expertise to scale their in vivo programs.